MedaSystems, a Menlo Park, CA-based SaaS platform for expanded access and investigator-initiated studies, has secured additional funding. 

Investors 

Existing investors, including the Debiopharm Innovation Fund, Nina Capital, and Young Sohn, a co-founder of Veeva Systems, participated in the round. 

MedaSystems Use of Funds 

The company will use the fresh funds to advance its AI-driven workflow platform.  

About MedaSystems 

MedaSystems is a developer of software designed to manage requests for experimental therapies, supporting expanded access, post-trial access, and investigator-initiated studies. Its SaaS platform automate workflows, manage treatment inquiries, improve patient access, and collect real-world data. The platform provides a centralized hub for healthcare providers, pharmaceutical companies, and regulatory partners to collaborate seamlessly. 

Funding Details 

Company: MedaSystems, Inc. 

Raised: Undisclosed 

Round: Seed 

Funding Date: March 2025 

Investors: Debiopharm Innovation Fund, Nina Capital, Young Sohn 

Company Website: https://medasystems.com/  

Software Category: Expanded Access and AI Workflow

Source: https://www.businesswire.com/news/home/20250305289858/en/